[go: up one dir, main page]

OA11307A - Drug delivery devices and methods for treatment ofviral and microbial infections and wasting syndro mes - Google Patents

Drug delivery devices and methods for treatment ofviral and microbial infections and wasting syndro mes Download PDF

Info

Publication number
OA11307A
OA11307A OA9900279A OA9900279A OA11307A OA 11307 A OA11307 A OA 11307A OA 9900279 A OA9900279 A OA 9900279A OA 9900279 A OA9900279 A OA 9900279A OA 11307 A OA11307 A OA 11307A
Authority
OA
OAPI
Prior art keywords
dmf
methyl
drug delivery
therapeutic composition
inclusive
Prior art date
Application number
OA9900279A
Other languages
English (en)
Inventor
Michelle Olga Patricia Visser
Original Assignee
Cryopreservation Tech Cc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/874,425 external-priority patent/US5935597A/en
Application filed by Cryopreservation Tech Cc filed Critical Cryopreservation Tech Cc
Publication of OA11307A publication Critical patent/OA11307A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/164Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
OA9900279A 1997-06-13 1999-12-10 Drug delivery devices and methods for treatment ofviral and microbial infections and wasting syndro mes OA11307A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/874,425 US5935597A (en) 1995-12-15 1997-06-13 Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes

Publications (1)

Publication Number Publication Date
OA11307A true OA11307A (en) 2003-10-24

Family

ID=25363728

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900279A OA11307A (en) 1997-06-13 1999-12-10 Drug delivery devices and methods for treatment ofviral and microbial infections and wasting syndro mes

Country Status (34)

Country Link
EP (1) EP1011567A1 (no)
JP (1) JP4531141B2 (no)
KR (1) KR20010013709A (no)
CN (1) CN1260703A (no)
AP (1) AP1629A (no)
AR (1) AR012970A1 (no)
AU (1) AU7831598A (no)
BG (1) BG103997A (no)
BR (1) BR9810095A (no)
CA (1) CA2295176A1 (no)
CZ (1) CZ298510B6 (no)
EA (1) EA200000011A1 (no)
EE (1) EE9900562A (no)
ES (1) ES2161187B1 (no)
FI (1) FI19992648A7 (no)
GB (1) GB2341319B (no)
HU (1) HUP0003034A2 (no)
ID (1) ID23516A (no)
IL (2) IL133396A0 (no)
IS (1) IS5289A (no)
LT (1) LT4714B (no)
LV (1) LV12490B (no)
NO (1) NO996117L (no)
NZ (1) NZ501669A (no)
OA (1) OA11307A (no)
PL (1) PL196256B1 (no)
RO (1) RO121252B1 (no)
SI (1) SI20191A (no)
SK (1) SK172299A3 (no)
TN (1) TNSN98086A1 (no)
TR (1) TR200000540T2 (no)
WO (1) WO1998056325A1 (no)
YU (1) YU66099A (no)
ZA (1) ZA984649B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060029162A (ko) * 2003-06-30 2006-04-04 알자 코포레이션 피부 피어싱 미세돌출부를 코팅하는 방법
CN1921829B (zh) * 2003-12-05 2010-05-05 纳米比亚医学调查研究有限公司 贴片

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US5534260A (en) * 1989-02-23 1996-07-09 University Of Utah Percutaneous drug delivery system
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US5624912A (en) * 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
ATE165345T1 (de) * 1992-02-20 1998-05-15 Merrell Pharma Inc Sulfonsaeurederivate zur behandlung von viruserkrankungen
TR199801066T2 (xx) * 1995-12-15 1998-08-21 Cryopreservation Technologies Cc Organ kriyokorumas� ve viral ve bakteryal enfeksiyonlar�n iyile�tirilmesi i�in bile�im.

Also Published As

Publication number Publication date
TNSN98086A1 (fr) 2005-03-15
LV12490B (en) 2000-12-20
FI19992648L (fi) 2000-02-03
GB2341319B (en) 2002-02-27
EP1011567A4 (en) 2000-06-28
ID23516A (id) 2000-04-27
YU66099A (sh) 2002-10-18
EE9900562A (et) 2000-06-15
CZ9904473A3 (cs) 2001-03-14
LT99148A (lt) 2000-07-25
PL196256B1 (pl) 2007-12-31
IS5289A (is) 1999-12-08
NZ501669A (en) 2001-09-28
BR9810095A (pt) 2001-11-13
ES2161187A1 (es) 2001-11-16
LV12490A (en) 2000-06-20
ZA984649B (en) 1999-12-17
AP1629A (en) 2006-07-11
GB2341319A (en) 2000-03-15
IL133396A (en) 2006-10-05
FI19992648A7 (fi) 2000-02-03
JP4531141B2 (ja) 2010-08-25
JP2002511862A (ja) 2002-04-16
PL338439A1 (en) 2000-11-06
AR012970A1 (es) 2000-11-22
LT4714B (lt) 2000-10-25
IL133396A0 (en) 2001-04-30
GB9929189D0 (en) 2000-02-02
AP9901708A0 (en) 1999-12-31
EA200000011A1 (ru) 2000-08-28
CN1260703A (zh) 2000-07-19
HUP0003034A2 (hu) 2000-12-28
SK172299A3 (en) 2000-09-12
TR200000540T2 (tr) 2000-09-21
CA2295176A1 (en) 1998-12-17
WO1998056325A1 (en) 1998-12-17
EP1011567A1 (en) 2000-06-28
NO996117D0 (no) 1999-12-10
ES2161187B1 (es) 2003-08-16
SI20191A (sl) 2000-10-31
BG103997A (bg) 2001-07-31
AU7831598A (en) 1998-12-30
RO121252B1 (ro) 2007-02-28
KR20010013709A (ko) 2001-02-26
CZ298510B6 (cs) 2007-10-24
NO996117L (no) 2000-02-11

Similar Documents

Publication Publication Date Title
Soudeyns et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog
Yamamoto et al. Human alpha-and beta-interferon but not gamma-suppress the in vitro replication of LAV, HTLV-III, and ARV-2
Zucker-Franklin et al. Megakaryocytes of human immunodeficiency virus-infected individuals express viral RNA.
Lundgren et al. Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus
Hammer et al. Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro
Hostetler et al. Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3'-deoxythymidine
US5935597A (en) Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes
Togo et al. Double-blind clinical assessment of ribavirin (virazole) in the prevention of induced infection with type B influenza virus
Carter et al. Activities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro
Kimes et al. Reduction of cerebral glucose utilization by the HIV envelope glycoprotein Gp-120
Richman Antiviral therapy of HIV infection
OA11307A (en) Drug delivery devices and methods for treatment ofviral and microbial infections and wasting syndro mes
NO881190L (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 9-(beta-d-deoxyribofuranosyl)-mucleosider.
Harbison et al. Effects of recombinant soluble CD4 (rCD4) on HIV-1 infection of monocyte/macrophages
Geleziunas et al. Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages
Biagiotti et al. Abnormalities of in vitro immunoglobulin production in apparently healthy haemophiliacs: relationship with alterations of T cell subsets and with HTLV-III seropositivity
Chokekijchai et al. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI
Gupta Therapy of AIDS and AIDS-related syndromes
Weber et al. Low-dose zidovudine in combination with either acyclovir or lymphoblastoid interferon-alpha in asymptomatic HIV-infected patients: a pilot study
US5182306A (en) Use of colchicine for the control of retroviruses
Kalnina et al. Evaluation of anti-HIV-1 (Retroviridae: Orthoretrovirinae: Lentivirus: Human immunodeficiency virus type 1) activity of 6HP and 3TC in vitro using MT-4 cell line variants with different replicative activity
Nakashima et al. Effect of HTLV-III on the macromolecular synthesis in HTLV-I carrying cell line, MT-4
JPH03227925A (ja) エイズ原因ウィルスに対する抗ウイルス剤
Fritsch et al. Anti-retroviral therapy in HIV-1-infected persons: Concepts and strategies
EP0380618A1 (en) The use of colchicine and related compounds for the manufacture of a medicament for the control of retroviruses